Search Results - "Giangrande, Paloma"

Aptamers: Cutting edge of cancer therapies by Shigdar, Sarah, Schrand, Brett, Giangrande, Paloma H., de Franciscis, Vittorio

“…The development of an aptamer-based therapeutic has rapidly progressed following the first two reports in the 1990s, underscoring the advantages of aptamer…”
Get full text

Aptamer-siRNA Chimeras: Discovery, Progress, and Future Prospects by Kruspe, Sven, Giangrande, Paloma H

“…Synthetic nucleic acid ligands (aptamers) have emerged as effective delivery tools for many therapeutic oligonucleotide-based drugs, including small…”
Get full text

Advances in mRNA non-viral delivery approaches by Ibba, Maria L., Ciccone, Giuseppe, Esposito, Carla L., Catuogno, Silvia, Giangrande, Paloma H.

“…[Display omitted] Messenger RNAs (mRNAs) present a great potential as therapeutics for the treatment and prevention of a wide range of human pathologies,…”
Get full text

Induction of tumour immunity by targeted inhibition of nonsense-mediated mRNA decay by Gilboa, Eli, Pastor, Fernando, Giangrande, Paloma H, Kolonias, Despina

“…The main reason why tumours are not controlled by the immune system is that, unlike pathogens, they do not express potent tumour rejection antigens (TRAs)…”
Get full text

Toward the full potential of mRNA therapeutics by McNamara, 2nd, James O, Giangrande, Paloma H

Get more information

The Nobel Prize awarded to pioneers of mRNA vaccines by Herzog, Roland W., Giangrande, Paloma H.

Get full text

Aptamers as Diagnostic Tools in Cancer by Ruiz Ciancio, Dario, Vargas, Mauricio R, Thiel, William H, Bruno, Martin A, Giangrande, Paloma H, Mestre, María Belén

“…Cancer is the second leading cause of death worldwide. Researchers have been working hard on investigating not only improved therapeutics but also on early…”
Get full text

Multifunctional Aptamer-miRNA Conjugates for Targeted Cancer Therapy by Esposito, Carla L, Cerchia, Laura, Catuogno, Silvia, De Vita, Gennaro, Dassie, Justin P, Santamaria, Gianluca, Swiderski, Piotr, Condorelli, Gerolama, Giangrande, Paloma H, de Franciscis, Vittorio

“…While microRNAs (miRNAs) clearly regulate multiple pathways integral to disease development and progression, the lack of safe and reliable means for specific…”
Get full text

On integrity by Bricker-Anthony, Courtney, Giangrande, Paloma H.

Get full text

Oligonucleotide aptamers: A next-generation technology for the capture and detection of circulating tumor cells by Dickey, David D., Giangrande, Paloma H.

“…•Circulating tumor cells (CTCs) are important for the metastatic spread of cancer.•Isolating and characterizing CTCs could provide valuable clinical…”
Get full text

Rapid identification of cell-specific, internalizing RNA aptamers with bioinformatics analyses of a cell-based aptamer selection by Thiel, William H, Bair, Thomas, Peek, Andrew S, Liu, Xiuying, Dassie, Justin, Stockdale, Katie R, Behlke, Mark A, Miller, Jr, Francis J, Giangrande, Paloma H

“…The broad applicability of RNA aptamers as cell-specific delivery tools for therapeutic reagents depends on the ability to identify aptamer sequences that…”
Get full text

Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors by Dassie, Justin P, Thomas, Gregory S, Thiel, Kristina W, Meyerholz, David K, McCaffrey, Anton P, McNamara, James O, Whitaker, Ryan M, Stockdale, Katie R, Liu, Xiu-ying, Giangrande, Paloma H

“…Systemic delivery remains a major obstacle in therapeutic applications of siRNAs. Using RNA aptamer–siRNA chimeras with enhanced silencing activity and…”
Get full text

mRNA therapy restores euglycemia and prevents liver tumors in murine model of glycogen storage disease by Cao, Jingsong, Choi, Minjung, Guadagnin, Eleonora, Soty, Maud, Silva, Marine, Verzieux, Vincent, Weisser, Edward, Markel, Arianna, Zhuo, Jenny, Liang, Shi, Yin, Ling, Frassetto, Andrea, Graham, Anne-Renee, Burke, Kristine, Ketova, Tatiana, Mihai, Cosmin, Zalinger, Zach, Levy, Becca, Besin, Gilles, Wolfrom, Meredith, Tran, Barbara, Tunkey, Christopher, Owen, Erik, Sarkis, Joe, Dousis, Athanasios, Presnyak, Vladimir, Pepin, Christopher, Zheng, Wei, Ci, Lei, Hard, Marjie, Miracco, Edward, Rice, Lisa, Nguyen, Vi, Zimmer, Mike, Rajarajacholan, Uma, Finn, Patrick F., Mithieux, Gilles, Rajas, Fabienne, Martini, Paolo G. V., Giangrande, Paloma H.

“…Glycogen Storage Disease 1a (GSD1a) is a rare, inherited metabolic disorder caused by deficiency of glucose 6-phosphatase (G6Pase-α). G6Pase-α is critical for…”
Get full text

Multivalent 4-1BB binding aptamers costimulate CD8+ T cells and inhibit tumor growth in mice by McNamara, James O, Kolonias, Despina, Pastor, Fernando, Mittler, Robert S, Chen, Lieping, Giangrande, Paloma H, Sullenger, Bruce, Gilboa, Eli

“…4-1BB is a major costimulatory receptor that promotes the survival and expansion of activated T cells. Administration of agonistic anti-4-1BB Abs has been…”
Get full text

mRNA Therapy Improves Metabolic and Behavioral Abnormalities in a Murine Model of Citrin Deficiency by Cao, Jingsong, An, Ding, Galduroz, Mikel, Zhuo, Jenny, Liang, Shi, Eybye, Marianne, Frassetto, Andrea, Kuroda, Eishi, Funahashi, Aki, Santana, Jordan, Mihai, Cosmin, Benenato, Kerry E., Kumarasinghe, E. Sathyajith, Sabnis, Staci, Salerno, Timothy, Coughlan, Kimberly, Miracco, Edward J., Levy, Becca, Besin, Gilles, Schultz, Joshua, Lukacs, Christine, Guey, Lin, Finn, Patrick, Furukawa, Tatsuhiko, Giangrande, Paloma H., Saheki, Takeyori, Martini, Paolo G.V.

“…Citrin deficiency is an autosomal recessive disorder caused by loss-of-function mutations in SLC25A13, encoding the liver-specific mitochondrial…”
Get full text

Impact of stereopure chimeric backbone chemistries on the potency and durability of gene silencing by RNA interference by Liu, Wei, Iwamoto, Naoki, Marappan, Subramanian, Luu, Khoa, Tripathi, Snehlata, Purcell-Estabrook, Erin, Shelke, Juili Dilip, Shah, Himali, Lamattina, Anthony, Pan, Qianli, Schrand, Brett, Favaloro, Frank, Bedekar, Mugdha, Chatterjee, Arindom, Desai, Jigar, Kawamoto, Tomomi, Lu, Genliang, Metterville, Jake, Samaraweera, Milinda, Prakasha, Priyanka Shiva, Yang, Hailin, Yin, Yuan, Yu, Hui, Giangrande, Paloma H, Byrne, Michael, Kandasamy, Pachamuthu, Vargeese, Chandra

“…Abstract Herein, we report the systematic investigation of stereopure phosphorothioate (PS) and phosphoryl guanidine (PN) linkages on siRNA-mediated silencing…”
Get full text

Synthetic human ABCB4 mRNA therapy rescues severe liver disease phenotype in a BALB/c.Abcb4-/- mouse model of PFIC3 by Wei, Guangyan, Cao, Jingsong, Huang, Pinzhu, An, Ping, Badlani, Disha, Vaid, Kahini A., Zhao, Shuangshuang, Wang, David Q-H., Zhuo, Jenny, Yin, Ling, Frassetto, Andrea, Markel, Arianna, Presnyak, Vladimir, Gandham, Srujan, Hua, Serenus, Lukacs, Christine, Finn, Patrick F., Giangrande, Paloma H., Martini, Paolo G.V., Popov, Yury V.

“…Progressive familial intrahepatic cholestasis type 3 (PFIC3) is a rare lethal autosomal recessive liver disorder caused by loss-of-function variations of the…”
Get full text

Cell-internalization SELEX: method for identifying cell-internalizing RNA aptamers for delivering siRNAs to target cells by Thiel, William H, Thiel, Kristina W, Flenker, Katie S, Bair, Tom, Dupuy, Adam J, McNamara, 2nd, James O, Miller, Francis J, Giangrande, Paloma H

“…After a decade of work to address cellular uptake, the principal obstacle to RNAi-based therapeutics, there is now well-deserved, renewed optimism about…”
Get more information

Analyzing HT-SELEX data with the Galaxy Project tools – A web based bioinformatics platform for biomedical research by Thiel, William H., Giangrande, Paloma H.

“…[Display omitted] •Analyzing aptamer high-throughput sequencing (HTS) data using the Galaxy platform.•Pre-process aptamer HTS data to isolate the variable…”
Get full text

Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras by Sullenger, Bruce A, McNamara, James O, Andrechek, Eran R, Wang, Yong, Viles, Kristi D, Rempel, Rachel E, Gilboa, Eli, Giangrande, Paloma H

“…Technologies that mediate targeted delivery of small interfering RNAs (siRNAs) are needed to improve their therapeutic efficacy and safety. Therefore, we have…”
Get full text